EUVIMEDSkopri EUVIMED
Übersichtsarbeit

Incretin hormone agonists: Current and emerging pharmacotherapy for obesity management

Ibrahim S Alhomoud iD, Azita H Talasaz iD, Preethi Chandrasekaran, Roy Brown iD, Anurag Mehta iD, Dave L Dixon iD

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2024

DOI: 10.1002/phar.4607 ↗

At a glance

Übersichtsarbeit in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2024. Written by Ibrahim S Alhomoud and 5 co-authors. Institution: Department of Pharmacy Practice, College of Pharmacy, Qassim University, Qassim, Saudi Arabia. Major MEDLINE topics: Incretins, Obesity, Anti-Obesity Agents. Cited 17 times so far (Crossref); 69 references.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Obesity continues to be a significant global health challenge, affecting over 800 million individuals worldwide. Traditional management strategies, including dietary, exercise, and behavioral interventions, often result in insufficient and unsustainable weight loss. Lifestyle modification remains the cornerstone of obesity management, providing the foundation for other strategies. While options such as bariatric surgery remain an effective intervention for severe obesity, it is associated with its own set of risks and is typically reserved for patients who have not achieved the desired results with pharmacotherapy and lifestyle interventions. Incretin hormone agonists represent a significant advancement in the pharmacotherapy of obesity, offering substantial weight reduction and cardiometabolic benefits. Agents like liraglutide, semaglutide, and tirzepatide supported by key clinical trials such as Satiety and Clinical Adipose Liraglutide Evidence (SCALE), Semaglutide Treatment Effect in People with Obesity (STEP) program trials, and Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT‐1) have demonstrated remarkable efficacy in promoting weight loss and improving metabolic outcomes. Additionally, novel therapies, including dual and triple incretin agonists, are under investigation and hold the potential for further advancements in obesity treatment. These novel therapies can be categorized by their mechanisms of action and route of administration into oral glucagon‐like peptide‐1 (GLP‐1) receptor agonists, triple agonists (targeting GLP‐1, glucose‐dependent insulinotropic polypeptide [GIP], and glucagon receptors), and glucagon receptor‐GLP‐1 receptor co‐agonists. Other innovative approaches include oral GIP‐GLP‐1 receptor co‐agonists, and the combination of long‐acting amylin receptor agonists with GLP‐1 receptor agonists. The ongoing development of incretin‐based therapies and the expanding availability of currently available agents are expected to enhance clinical outcomes further and reduce the burden of obesity‐related health complications. This review aims to discuss the mechanisms and efficacy of current and emerging incretin hormone agonists for obesity management.

Subjects

MeSH terms (MEDLINE)

IncretinsObesityAnti-Obesity AgentsHumansGlucagon-Like PeptidesWeight LossObesity ManagementLiraglutideSemaglutide

Author keywords

incretinliraglutideobesitysemaglutidetirzepatideweight loss

Substances

IncretinsAnti-Obesity AgentsGlucagon-Like PeptidesLiraglutideSemaglutide

Authors and institutions

  • Department of Pharmacy Practice, College of Pharmacy, Qassim University, Qassim, Saudi Arabia.
  • Department of Pharmacy, New York-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, USA.
  • UT Southwestern Medical Center Dallas, Dallas, Texas, USA.
  • Health Sciences Library, Virginia Commonwealth University Libraries, Richmond, Virginia, USA.
  • Pauley Heart Center, Virginia Commonwealth University, Richmond, Virginia, USA.
  • Department of Pharmacotherapy & Outcomes Science, Virginia Commonwealth University School of Pharmacy, Richmond, Virginia, USA.

ORCID profiles: Ibrahim S Alhomoud, Azita H Talasaz, Roy Brown, Anurag Mehta, Dave L Dixon

Cite

APA

Alhomoud, I. S., Talasaz, A. H., Chandrasekaran, P., Brown, R., Mehta, A., & Dixon, D. L. (2024). Incretin hormone agonists: Current and emerging pharmacotherapy for obesity management. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. https://doi.org/10.1002/phar.4607

Vancouver

Alhomoud IS, Talasaz AH, Chandrasekaran P, Brown R, Mehta A, Dixon DL. Incretin hormone agonists: Current and emerging pharmacotherapy for obesity management. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2024. doi:10.1002/phar.4607

BibTeX
@article{Alhomoud2024,
  author = {Alhomoud, Ibrahim S and Talasaz, Azita H and Chandrasekaran, Preethi and Brown, Roy and Mehta, Anurag and Dixon, Dave L},
  title = {Incretin hormone agonists: Current and emerging pharmacotherapy for obesity management},
  journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
  year = {2024},
  doi = {10.1002/phar.4607}
}
Start for free →